Commercialization of the Xalkori Pediatric Multiparticulate Product Using Quality-by-Design Principles
A pediatric dosage form for crizotinib (Xalkori) was commercialized using quality-by-design principles in a material-sparing fashion. The dosage form consists of spherical multiparticulates (microspheres or pellets) that are coated and encapsulated in capsules for opening. The crizotinib (Xalkori)-c...
Furkejuvvon:
| Váldodahkkit: | , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
MDPI AG
2024-08-01
|
| Ráidu: | Pharmaceutics |
| Fáttát: | |
| Liŋkkat: | https://www.mdpi.com/1999-4923/16/8/1027 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|